Combining Doxycycline With Bone-Targeted Therapy in Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if women with bone metastases from breast cancer will
benefit from the addition of doxycycline to their standard bone-targeted therapy.
Participants will be asked to take 100 mg of Doxycycline orally twice a day for 12 weeks.
Blood and tissue collection will further define the mechanism of the benefits if there are
any.